Diagnostic accuracy of the Aspergillus‐specific bronchoalveolar lavage lateral‐flow assay in haematological malignancy patients
Authors:
Abstract
Summary: We evaluated the performance of the Aspergillus‐specific lateral‐flow device (LFD) test for diagnosing invasive pulmonary aspergillosis (IPA) in patients with underlying haematological malignancies. Participating centres were the two Austrian University Hospitals of Graz and Innsbruck. LFD performance was evaluated with 95 bronchoalveolar lavage fluid (BALF) samples from 72 patients collected prospectively in Graz, and with 24 BALF bio bank samples from 23 patients (21 samples with probable IPA) in Innsbruck. Invasive fungal infections were classified according to the revised European Organization of Research and Treatment of Cancer/Mycoses Study Group criteria. Overall, 27 patients (30 samples) had probable IPA, 32 (43 samples) possible and 36 (46 samples) did not fulfil IPA criteria. The vast majority of patients – in particular those with probable IPA – received mould‐active treatment before bronchoscopy. Sensitivity, specificity, positive predictive value and negative‐predictive‐value for probable IPA diagnosis using the BALF‐LFD test were 71%, 76%, 35% and 94% for the Graz cohort. Sensitivity of the BALF‐LFD test for probable IPA was 57% in Innsbruck bio bank samples. Our results indicate that the BALF‐LFD‐test provides fast results with moderate sensitivities in patients with underlying haematological malignancies. Similar to other diagnostic tests and biomarkers sensitivity of the test may be influenced by ongoing systemic mould‐active treatment.Keywords
Funding Information
- Österreichische Nationalbank (15346)
This publication has 36 references indexed in Scilit:
- Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignanciesJournal of Antimicrobial Chemotherapy, 2012
- Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samplesEuropean Journal of Haematology, 2012
- Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational studyJournal of Antimicrobial Chemotherapy, 2012
- Prospective Evaluation of Clinical and Biological Markers To Predict the Outcome of Invasive Pulmonary Aspergillosis in Hematological PatientsJournal of Clinical Microbiology, 2012
- Earlier Response Assessment in Invasive Aspergillosis Based on the Kinetics of Serum Aspergillus Galactomannan: Proposal for a New DefinitionClinical Infectious Diseases, 2011
- Galactomannan Testing in Bronchoalveolar Lavage Fluid Facilitates the Diagnosis of Invasive Pulmonary Aspergillosis in Patients with Hematologic Malignancies and Stem Cell Transplant RecipientsTransplantation and Cellular Therapy, 2011
- UPDATE ON THE LABORATORY DIAGNOSIS OF INVASIVE FUNGAL INFECTIONSMediterranean Journal of Hematology and Infectious Diseases, 2011
- Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantationBlood, 2010
- Development of an Immunochromatographic Lateral-Flow Device for Rapid Serodiagnosis of Invasive AspergillosisClinical and Vaccine Immunology, 2008
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008